NASDAQ
DCTH

Delcath Systems Inc

Medical Devices
Healthcare

Prices are adjusted according to historical splits.

Delcath Systems Inc Stock Price

Vitals

Today's Low:
$4.78
Today's High:
$5.05
Open Price:
$4.85
52W Low:
$2.34
52W High:
$7.99
Prev. Close:
$4.9
Volume:
219185

Company Statistics

Market Cap.:
$74.24 million
Book Value:
-1.297
Revenue TTM:
$2.94 million
Operating Margin TTM:
-1151.74%
Gross Profit TTM:
$2.03 million
Profit Margin:
0%
Return on Assets TTM:
-73.03%
Return on Equity TTM:
-694.27%

Company Profile

Delcath Systems Inc had its IPO on 2018-05-29 under the ticker symbol DCTH.

The company operates in the Healthcare sector and Medical Devices industry. Delcath Systems Inc has a staff strength of 52 employees.

Stock update

Shares of Delcath Systems Inc opened at $4.85 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $4.78 - $5.05, and closed at $4.81.

This is a -1.84% slip from the previous day's closing price.

A total volume of 219,185 shares were traded at the close of the day’s session.

In the last one week, shares of Delcath Systems Inc have slipped by -1.03%.

Delcath Systems Inc's Key Ratios

Delcath Systems Inc has a market cap of $74.24 million, indicating a price to book ratio of 7.0098 and a price to sales ratio of 7.3084.

In the last 12-months Delcath Systems Inc’s revenue was $2.94 million with a gross profit of $2.03 million and an EBITDA of $-33707000. The EBITDA ratio measures Delcath Systems Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Delcath Systems Inc’s operating margin was -1151.74% while its return on assets stood at -73.03% with a return of equity of -694.27%.

In Q1, Delcath Systems Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 57.9%.

Delcath Systems Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-3.39 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Delcath Systems Inc’s profitability.

Delcath Systems Inc stock is trading at a EV to sales ratio of 9.1037 and a EV to EBITDA ratio of -1.3212. Its price to sales ratio in the trailing 12-months stood at 7.3084.

Delcath Systems Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$30.60 million
Total Liabilities
$13.41 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Delcath Systems Inc ended 2024 with $30.60 million in total assets and $0 in total liabilities. Its intangible assets were valued at $30.60 million while shareholder equity stood at $-13076000.00.

Delcath Systems Inc ended 2024 with $4.94 million in deferred long-term liabilities, $13.41 million in other current liabilities, 101000.00 in common stock, $-466483000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $24.22 million and cash and short-term investments were $24.22 million. The company’s total short-term debt was $3,863,000 while long-term debt stood at $5.80 million.

Delcath Systems Inc’s total current assets stands at $29.02 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $458000.00 compared to accounts payable of $2.43 million and inventory worth $2.34 million.

In 2024, Delcath Systems Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Delcath Systems Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$4.81
52-Week High
$7.99
52-Week Low
$2.34
Analyst Target Price
$16.4

Delcath Systems Inc stock is currently trading at $4.81 per share. It touched a 52-week high of $7.99 and a 52-week low of $7.99. Analysts tracking the stock have a 12-month average target price of $16.4.

Its 50-day moving average was $4.8 and 200-day moving average was $4.95 The short ratio stood at 23.83 indicating a short percent outstanding of 0%.

Around 287.8% of the company’s stock are held by insiders while 1306.6% are held by institutions.

Frequently Asked Questions About Delcath Systems Inc

The stock symbol (also called stock or share ticker) of Delcath Systems Inc is DCTH

The IPO of Delcath Systems Inc took place on 2018-05-29

Similar Industry Stocks (Medical Devices)

Last Price
Chg
Chg%
$27
-0.15
-0.55%
$35.63
0.26
+0.74%
Waterbase Limited (WATERBASE)
$82.47
-6.06
-6.85%
$16.89
0
0%
$2.2
0.15
+7.32%
$26.45
-1.07
-3.89%
KRBL Limited (530813)
$425.55
-29.05
-6.39%
$31.2
-2.21
-6.61%
$7.73
-0.39
-4.8%
$747.55
-3.35
-0.45%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Address

1633 Broadway, New York, NY, United States, 10019